Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Arbidol for COPD Exacerbations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03851991
Recruitment Status : Recruiting
First Posted : February 22, 2019
Last Update Posted : October 11, 2019
Information provided by (Responsible Party):
LI ZHAO, Shengjing Hospital

Brief Summary:

Chronic Obstructive Pulmonary Disease (COPD) is currently the fourth leading cause of death in the world. Acute exacerbations of COPD (AECOPD) are the most important events in the course of the disease because they negatively impact health status, life quality, disease progression, patients survival and economic and social burden. Reducing frequency of AECOPD is the key goal of management for COPD. Since respiratory viral infections are the mainly trigger of AECOPD, anti-viral therapy would be the affective method to prevent the exacerbation or reduce the attack severity. However, there are no positive study results of treating or preventing AECOPD used by current anti-viral drugs approved by FDA so far.

Arbidol is a non-nucleoside antiviral drug. It inhibits viral DNA and RNA synthesis by inhibiting fusion of viral lipid vesicle membrane with host cell membranes. Arbidol has broad-spectrum antiviral activity. In addition to inhibition of influenza virus, it against a variety of viruses including respiratory syncytial disease (RSV), parainfluenza virus, human rhinovirus, coxsackie virus (CV), adenovirus (ADV) and so on. In recent years, some fundamental and clinical researches have shown that arbidol has a significant role in prevention and treatment of influenza virus and other acute respiratory viral infections. Therefore, the investigators speculate that Arbidol will effectively control COPD combined with upper respiratory virus infection, thereby reducing acute exacerbations of COPD.

This is a prospective, multicenter, randomized, double-blind, placebo-controlled, 52-week study. The purpose of this study is to evaluate the efficacy and safety of arbidol in improving the frequency and extent of moderate or severe acute exacerbations in patients with COPD. Eligible subjects will be randomly assigned to treatment group or placebo group at a 2:1 ratio. Subjects of treatment group receive an on-demand arbidol 200 mg three times per day while placebo group receives matched placebo. When the subject has a new respiratory infection, original respiratory symptoms worsen, or fever (the lower body temperature is greater than 37.3℃), oral medication is given immediately. The subjects are required to receive the first dose of drug within 8 hours after the symptoms of upper respiratory tract infection.

Condition or disease Intervention/treatment Phase
COPD Patients Drug: Arbidol Drug: Placebos Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 990 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 52-week Multicenter, Randomized, Double-blind, Placebo-controlled, Prospective Study to Evaluate the Efficacy and Safety of Arbidol Hydrochloride Capsules in Reducing the Frequency of Moderate or Severe Acute Exacerbations in Patients With Chronic Obstructive Pulmonary Disease.
Actual Study Start Date : August 30, 2019
Estimated Primary Completion Date : August 31, 2021
Estimated Study Completion Date : August 31, 2022

Arm Intervention/treatment
Active Comparator: arbidol
200mg, three times per day, for 2-5 Days.
Drug: Arbidol

Placebo Comparator: Placebos
two capsules, three times per day, for 2-5 Days.
Drug: Placebos

Primary Outcome Measures :
  1. Frequency of moderate or severe acute exacerbation in patients with chronic obstructive pulmonary disease [ Time Frame: 52 weeks ]

Secondary Outcome Measures :
  1. The frequency of Acute exacerbation of patients leads to hospitalization [ Time Frame: 52 weeks ]
  2. The intervals to the next acute exacerbation after the first use of the study drug [ Time Frame: 52 weeks ]
  3. To assess the change of FEV1 from baseline [ Time Frame: 52 weeks ]
  4. Mean duration of moderate or severe acute exacerbation in chronic obstructive pulmonary disease [ Time Frame: 52 weeks ]
  5. Throat swab and virus separation experiment to detect the composition of respiratory viruses in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) requiring hospitalization [ Time Frame: 52 weeks ]
  6. Number of unscheduled visits to a clinic for COPD exacerbation [ Time Frame: 52 weeks ]
  7. Number of emergency room visits for AECOPD [ Time Frame: 52 weeks ]
  8. Number of hospitalizations due to AECOPD [ Time Frame: 52 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients from Outpatient clinic.
  2. Informed consent and assent must be obtained before any study assessment is performed.
  3. Aged ≥40 years.
  4. Continuous respiratory symptoms, such as chronic cough, sputum or shortness of breath etc.
  5. Exposure to risk factors: Host factors, Tobacco, Occupation, Indoor/outdoor pollution
  6. FEV1/FVC less than 0.70 after withholding bronchodilator.
  7. 2 or more acute exacerbations of COPD within the 12 months prior to visit 0. Or more than 1 hospitalizations due to AECOPD within the 12 months prior to visit 0.
  8. Good compliance.

Exclusion Criteria:

  1. Patients with any chronic diseases except COPD which in the opinion of the investigator may interfere with study evaluation or optimal participation in the study.
  2. Patients with a history of chronic lung disease other than COPD, including (but not limited to) active tuberculosis, lung cancer, clinically significant bronchiectasis, primary pulmonary hypertension, sarcoidosis, interstitial lung disease, asthma (other than asthma COPD overlap), severe cor pulmonale.
  3. Patients with acute coronary syndrome(ACS) or acute left heart failure within the 6 months prior to visit 0. Patients accepted Coronary interventional therapy or coronary artery bypass grafting due to ACS within the 3 months prior to visit 0.
  4. Patients with uncontrolled hypertension.
  5. Patients who started oral >10mg prednisolone or Equivalent systemic corticosteroids within 4 weeks prior to Visit 1. Or patients who received antibiotics within 4 weeks prior to Visit 1. Or patients who received standard treatment for COPD within 4 weeks prior to Visit 1. Or use of other investigational drugs within 5 half-lives of enrollment, or within 30 days, whichever is longer.
  6. Patients who received influenza vaccine or other viral vaccine within the 12 months prior to visit 0.
  7. The end of AECOPD therapy was within the 4 weeks prior to visit 0. Or Occurrence of AECOPD within the 6 weeks prior to visit 0.
  8. History of arbidol sensitivity.
  9. No person directly associated with the administration of the study is allowed to participate as a study subject.
  10. Use of other investigational intervention within within 30 days.
  11. Patients with obviously abnormal liver function, AST or ALT>2 times the upper limit of normal value or total bilirubin>1.3 times the upper limit of normal value.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03851991

Layout table for location contacts
Contact: Yu Li, Master 18940256331

Layout table for location information
China, Liaoning
Shenjing Hospital Recruiting
Shenyang, Liaoning, China, 110004
Contact: Yu Li, MD    86-18940256331   
Contact: Shuang Bai, MD    86-15382098355   
Principal Investigator: Li Zhao, MD         
Sponsors and Collaborators
Shengjing Hospital
Layout table for additonal information
Responsible Party: LI ZHAO, Professor, Shengjing Hospital Identifier: NCT03851991    
Other Study ID Numbers: HX002
First Posted: February 22, 2019    Key Record Dates
Last Update Posted: October 11, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by LI ZHAO, Shengjing Hospital: